BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

arGEN-X 

Dr Molewaterplein 50

Rotterdam    3015 GE  The Nederlands
Phone: 31-0-10-7038441 Fax: 31-0-10-7038440


SEARCH JOBS




Industry
Biotechnology

Segment
Start Up





 Company News
Forbion Announces Closing Of Initial Public Offering Of Portfolio Company arGEN-X 7/9/2014 9:09:43 AM
Dutch Biotech arGEN-X Plans To Go Public In Brussels 6/10/2014 7:26:33 AM
arGEN-X Inks Long-Term Alliance With Shire Pharmaceuticals (SHPG) Worth $20.4 Million 6/4/2014 6:31:23 AM
arGEN-X Uses Its Simple Antibody™ Platform To Identify Four "Hotspots" On MET As Targets For Its Therapeutic Antibody Program 4/7/2014 9:23:05 AM
arGEN-X Raises EUR 5 Million From PMV in Extension of EUR 32.5 Million Series B 11/4/2013 9:25:36 AM
arGEN-X and de Duve Institute at the Catholique University of Louvain to Collaborate on Novel Immunomodulation Therapy in Cancer 11/4/2013 9:23:48 AM
arGEN-X Reaches Milestone in Simple Antibody™ Research and Product Development Collaboration With Shire Pharmaceuticals (SHPG) 9/19/2013 10:00:42 AM
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer 9/17/2013 9:05:24 AM
arGEN-X Identifies Potent Antibody Antagonists Against Complex Chronic Pain Target Nav1.7 9/12/2013 9:24:28 AM
arGEN-X Grants Licenses to Its NHance™ Antibody Half-Life Extension Technology 8/6/2013 9:39:06 AM
123